NCT05966480Phase 2Active not recruiting

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Study sponsor: Alumis Inc · ALMS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-23Actual
Enrollment · participants408Actual
Source updated2026-07-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 1 Jul 2026. After: 23 Jun 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview